Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma

References

1. Casneuf, V, Borbath, I, Van den Eynde, M, Verheezen, Y, Demey, W, Verstraete, AG, et al.. Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur). Acta Clin Belg 2021. https://doi.org/10.1080/17843286.2020.1870855 [Epub ahead of print].Search in Google Scholar

2. INCa and HAS. Recherche de déficit en dihydropyrimidine déshydrogenase en vue de prévenir certaines toxicités sévères survenant sous traitement comportant des fluoropyrimidines (5-fluorouracile), Recommandations et référentiels. France: INCa, HAS; décembre 2018.Search in Google Scholar

3. Meulendijks, D, Henricks, LM, Jacobs, BAW, Aliev, A, Deenen, MJ, de Vries, N, et al.. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 2017;116:1415–24. https://doi.org/10.1038/bjc.2017.94.Search in Google Scholar

4. Sistonen, J, Büchel, B, Froehlich, TK, Kummer, D, Fontana, S, Joerger, M, et al.. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics 2014;15:1653–66. https://doi.org/10.2217/pgs.14.126.Search in Google Scholar

5. Jiang, H, Lu, J, Ji, J. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 2004;141:616–23. https://doi.org/10.1038/sj.bjp.0705651.Search in Google Scholar

6. Henricks, LM, Jacobs, BAW, Meulendijks, D, Pluim, D, van den Broek, D, de Vries, N, et al.. Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers. Br J Clin Pharmacol 2018;84:2761–9. https://doi.org/10.1111/bcp.13719.Search in Google Scholar

7. Jacobs, BA, Deenen, MJ, Pluim, D, van Hasselt, JG, Krähenbühl, MD, van Geel, RM, et al.. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. Br J Clin Pharmacol 2016;82:706–16. https://doi.org/10.1111/bcp.13007.Search in Google Scholar

8. Jacobs, BA, Rosing, H, De Vries, N, Meulendijks, D, Henricks, LM, Schellens, JH, et al.. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. J Pharm Biomed Anal 2016;126:75–82. https://doi.org/10.1016/j.jpba.2016.04.039.Search in Google Scholar

9. Coudoré, F, Roche, D, Lefeuvre, S, Faussot, D, Billaud, EM, Loriot, M-A, et al.. Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma. Chromatogr Sci 2012;50:877–84. https://doi.org/10.1093/chromsci/bms085.Search in Google Scholar

10. CLSI. Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved Guideline – Third Edition. CLSI EPC28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.Search in Google Scholar

11. Sandberg, S, Fraser, CG, Horvath, AR, Jansen, R, Jones, G, Oosterhuis, W, et al.. Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med 2015;53:833. https://doi.org/10.1515/cclm-2015-0067.Search in Google Scholar

12. Thomas, F, Maillard, M, Launay, M, Tron, C, Etienne-Grimaldi, M-C, Gautier-Veyret, E, et al.. Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation. Ann Oncol 2021;32:810–1. https://doi.org/10.1016/j.annonc.2021.02.020.Search in Google Scholar